BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED
BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED
Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic
 accuracy for congestive heart failure (CHF). Limited information is available regarding
 economic outcomes attributable to BNP assay. The aim of this study was to assess the economic
 impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).
Dyspneic patients 65 years were enrolled in a randomized, controlled trial; hemodynamically
 unstable patients were excluded. BNP (Biosite assay) levels were measured prior to physician
 assessment with randomization in 1:1 ratio to either BNP 1) level reported or 2) level not
 reported. ED physicians made triage decisions guided by clinical judgment and nomogram to aid
 in interpretation of BNP level. Primary outcome was mean total hospital cost per subject.
 Secondary outcomes included admission rate, service assignment, discharge diagnosis and
 length of stay. Differences between groups were compared by t-test with bootstrap. Costs
 reflect 2005 constant dollars.
Inclusion Criteria:

 -  Dyspneic patients 65 years or older presenting to the ED with chief complaint of
 shortness of breath.

 Exclusion Criteria:

 -  hemodynamically unstability